Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

VAXART, INC. VXRT

Healthcare — Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

VAXART, INC. (VXRT) Business Profile

Company Overview

Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company was founded in 2004 and has since focused on developing oral recombinant vaccines based on its proprietary oral vaccine platform. Vaxart’s mission is to revolutionize the way vaccines are delivered by creating oral tablet vaccines that are easier to administer, store, and distribute compared to traditional injectable vaccines.

The company is led by a team of experienced professionals in the biotechnology and pharmaceutical industries. Andrei Floroiu serves as the Chief Executive Officer (CEO), bringing extensive expertise in healthcare investment and strategic leadership. Other key members of the leadership team include Dr. Sean Tucker, the Chief Scientific Officer (CSO), who has been instrumental in developing Vaxart’s oral vaccine platform, and Philip Lee, the Chief Financial Officer (CFO), who oversees the company’s financial strategy and operations.

Core Business Segments

Vaxart operates primarily in the biotechnology and pharmaceutical sectors, with a focus on vaccine development. The company’s core business segments include:

Oral Vaccine Platform

Vaxart’s proprietary oral vaccine platform is the cornerstone of its business. This platform uses a non-replicating adenovirus type 5 (Ad5) vector to deliver antigens in a tablet form. The oral delivery method offers several advantages, including ease of administration, elimination of the need for needles, and improved stability for storage and transportation.

Vaccine Development Programs

Vaxart is actively developing vaccines for a range of infectious diseases, including:

  • COVID-19: Vaxart is working on an oral tablet vaccine for COVID-19, aiming to provide a needle-free alternative to existing vaccines. The company believes its oral vaccine could offer mucosal immunity, which may help prevent infection at the point of entry.
  • Norovirus: Vaxart is developing an oral vaccine for norovirus, a leading cause of acute gastroenteritis worldwide. The vaccine is currently in clinical trials.
  • Seasonal Influenza: The company is also working on an oral flu vaccine that could simplify vaccination campaigns and improve compliance.
  • Other Programs: Vaxart has preclinical programs targeting other infectious diseases, including respiratory syncytial virus (RSV) and human papillomavirus (HPV).

Business Model

Vaxart’s business model is centered around the research, development, and commercialization of oral vaccines. The company generates revenue through partnerships, licensing agreements, and government grants. Key elements of its business model include:

  • Research and Development (R&D): Vaxart invests heavily in R&D to advance its vaccine candidates through clinical trials and regulatory approval.
  • Collaborations and Partnerships: The company collaborates with government agencies, non-profit organizations, and pharmaceutical companies to fund and accelerate its vaccine development programs.
  • Licensing and Royalties: Vaxart plans to license its oral vaccine platform to other companies, generating revenue through upfront payments, milestone payments, and royalties.

Strategic Direction

Vaxart’s strategic direction focuses on expanding its pipeline of oral vaccines, advancing its existing candidates through clinical trials, and exploring new applications for its oral vaccine platform. Key strategic priorities include:

  • Pipeline Expansion: The company aims to develop vaccines for additional infectious diseases and explore therapeutic applications for its platform.
  • Regulatory Approvals: Vaxart is working to achieve regulatory approvals for its lead candidates, including the COVID-19 and norovirus vaccines.
  • Global Accessibility: By offering oral vaccines that are easier to store and distribute, Vaxart aims to improve vaccine accessibility in low- and middle-income countries.
  • Sustainability Goals: The company is committed to reducing the environmental impact of vaccine production and distribution by eliminating the need for cold storage and single-use syringes.

Competitive Landscape

Vaxart operates in a highly competitive industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Pfizer and Moderna: These companies dominate the COVID-19 vaccine market with their mRNA-based vaccines. Vaxart’s oral vaccine offers a differentiated approach but faces significant competition.
  • Novavax: Novavax is developing protein-based vaccines for COVID-19 and other diseases, posing a competitive threat to Vaxart’s pipeline.
  • Emergent BioSolutions: This company focuses on vaccines and therapeutics for infectious diseases, overlapping with Vaxart’s target markets.
  • Other Biotech Firms: Smaller biotech companies developing innovative vaccine technologies also compete with Vaxart for funding, partnerships, and market share.

Risk Factors

Vaxart faces several risks that could impact its business and financial performance, including:

  • Regulatory Risks: The company’s vaccine candidates must undergo rigorous clinical trials and regulatory reviews, which are time-consuming and expensive.
  • Market Dependence: Vaxart’s success depends on the commercial viability of its oral vaccines, which are still in development.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Competition: Intense competition from established players and emerging biotech firms could limit Vaxart’s market share.
  • Financial Risks: As a clinical-stage company, Vaxart has limited revenue and relies on external funding to finance its operations.

Recent Developments

Vaxart has made significant progress in advancing its vaccine candidates and expanding its capabilities. Recent developments include:

  • COVID-19 Vaccine Trials: The company has completed Phase 1 clinical trials for its oral COVID-19 vaccine and is preparing for Phase 2 trials.
  • Norovirus Vaccine Progress: Vaxart’s norovirus vaccine candidate has shown promising results in clinical trials, with plans to advance to later-stage studies.
  • Partnerships and Funding: Vaxart has secured funding from government agencies and non-profit organizations to support its vaccine development programs.
  • Platform Innovations: The company continues to refine its oral vaccine platform, exploring new delivery mechanisms and applications.

Investment Considerations

Investors considering Vaxart should weigh the company’s strengths and risks:

Strengths

  • Innovative Technology: Vaxart’s oral vaccine platform offers a unique approach to vaccine delivery.
  • Diverse Pipeline: The company is developing vaccines for multiple infectious diseases, reducing reliance on a single product.
  • Experienced Leadership: Vaxart’s management team has a strong track record in biotechnology and pharmaceuticals.

Risks

  • Clinical and Regulatory Uncertainty: The success of Vaxart’s vaccine candidates depends on positive clinical trial results and regulatory approvals.
  • Financial Dependence: The company relies on external funding and may need to raise additional capital.
  • Competitive Pressure: Vaxart faces intense competition from established players and emerging biotech firms.

Conclusion

Vaxart, Inc. is a pioneering biotechnology company with a mission to transform vaccine delivery through its innovative oral vaccine platform. While the company faces significant challenges, including regulatory hurdles and competition, its diverse pipeline and unique technology position it as a potential leader in the vaccine industry. With continued progress in clinical trials and strategic partnerships, Vaxart has the potential to achieve long-term growth and make a meaningful impact on global health.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us